CIK 0001583648 · Non-accelerated filer<br>Smaller reporting company
PALVELLA THERAPEUTICS, INC.
Sign in to watch- Ticker
- PVLA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 300784346
- Phone
- (484) 253-1461
- Business address
- 353 W. LANCASTER AVENUE, SUITE 200, WAYNE, PA, 19087
- Former names
- PIERIS PHARMACEUTICALS, INC., Marika Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,725,861
- in 7 filings, $11.7M under 10b5-1 plans
Net −$11,725,861. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-24 | Bures Thomas Chief Financial Officer | Grant or award · Stock Option (right to buy) | +249,080 | 249,080 | ||
| 2023-02-24 | Kaufmann Hitto Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +249,080 | 249,080 | ||
| 2023-02-24 | Mousa Ahmed Chief Business Officer | Grant or award · Stock Option (Right to buy) | +249,080 | 249,080 | ||
| 2023-02-24 | Olwill Shane Chief Development Officer | Grant or award · Stock Option (Right to buy) | +249,080 | 249,080 | ||
| 2023-02-24 | Yoder Stephen S. Chief Executive Officer | Grant or award · Stock Option (Right to buy) | +634,021 | 634,021 | ||
| 2022-06-22 | Barbier Ann Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-22 | Said Maya R. Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-22 | GERAGHTY JAMES A Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2022-06-22 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-22 | KIRITSY CHRISTOPHER P Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-22 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-22 | Sherman Matthew L Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-05-13 | Demuth Tim Chief Medical Officer | Purchase | +6,000 | $1.71 | $10K | 6,000 |
| 2022-02-22 | Demuth Tim Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +100,000 | 100,000 | ||
| 2022-02-22 | Mousa Ahmed Chief Business Officer | Grant or award · Stock Option (Right to buy) | +215,819 | 215,819 | ||
| 2022-02-22 | Olwill Shane Chief Development Officer | Grant or award · Stock Option (Right to buy) | +215,819 | 215,819 | ||
| 2022-02-22 | Bures Thomas Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +215,819 | 215,819 | ||
| 2022-02-22 | Kaufmann Hitto SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +215,819 | 215,819 | ||
| 2022-02-22 | Yoder Stephen S. Chief Executive Officer | Grant or award · Stock Option (Right to buy) | +625,874 | 625,874 | ||
| 2021-08-30 | Olwill Shane Chief Development Officer | Option exercise | +38,400 | $1.52 | $58K | 43,038 |
Page 11 of 12 · 232 trades